everolimus
Not Tagged
['everest', 'rcc,(-irccs),(-srcc),(-urcc)']
#asco22 oral presentation on phase 3 everest trial s primary results of adjuvant rx with everolimus in #kidneycancer rcc post surgery barely missed the primary endpoint in all patients , benefit only high risk patients 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E